APOE and early-onset autosomal dominant Alzheimer disease: Based on cumulative evidence from that and numerous other human and animal studies, researchers involved in the National Institute on Aging’s Alzheimer’s Disease Sequencing Project reached a consensus supporting the view that lowering APOE4 levels constitutes a rational therapeutic strategy, particularly in individuals of African and European ancestry carrying the APOE ε4 allele [60].